HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Psychiatry
Meta-analysis
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
May 1, 2026
Diabetes & Endocrinology
Meta-analysis
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
May 1, 2026
Cardiology
Cohort
Baseline vitamin D levels linked to semaglutide glycemic and weight outcomes in type 2 diabetes
Higher Vitamin D levels help Semaglutide work better for diabetes.
This observational cohort study of 5,384 adults with type 2 diabetes found that higher baseline vitamin D levels were associated with greate…
New data shows higher Vitamin D levels help Semaglutide lower blood sugar and weight more effectively in diabetes patients.
Frontiers
Apr 28, 2026
Diabetes & Endocrinology
Phase III
Semaglutide high dose for weight reduction in people with Type 2 Diabetes
New drug helps obese diabetics lose weight and control sugar
This randomized controlled trial in 512 people with excess weight and Type 2 Diabetes compared high-dose semaglutide to placebo and lower do…
New research shows a specific injection helps people with obesity and diabetes lose weight and control their blood sugar levels better than …
CT.gov
Apr 27, 2026
Drug Pipeline
Sys. Review
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Frontiers
Apr 27, 2026
Diabetes & Endocrinology
Meta-analysis
Network Meta-Analysis Finds Tirzepatide and Semaglutide Most Effective for Weight Loss in Adults
New Weight Loss Drugs Protect Your Heart and Lower Death Risk
A systematic review and network meta-analysis of 63,909 adults found that all obesity medications produced greater weight loss than placebo.…
New data from 66 trials shows top obesity drugs significantly reduce heart events and death while helping with liver and joint pain issues f…
medRxiv
Apr 24, 2026
Diabetes & Endocrinology
Cohort
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
medRxiv
Apr 24, 2026
Oncology
Review of observational data links semaglutide and tirzepatide to survival in breast cancer
Semaglutide linked to lower death rates in breast cancer patients compared to other diabetes drugs
This review synthesized observational, propensity-matched analyses of patients with pre-existing breast cancer. It reported improved overall…
In routine care, semaglutide users with breast cancer had significantly lower death rates and less metastatic disease than those on other co…
medRxiv
Apr 24, 2026
Drug Pipeline
Computational model review predicts dual optima for combination therapy in ageing
New math model shows combining drugs could slow aging better than weight loss alone
This review of a computational model explores combination therapy with semaglutide, SGLT2 inhibitors, metformin, and rapamycin for ageing. I…
A new computer model reveals that fixing blood sugar and slowing aging are separate tasks, meaning some drugs might help you live longer eve…
medRxiv
Apr 24, 2026
Diabetes & Endocrinology
Phase III
Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
Tirzepatide Saves Money and Health Over Semaglutide
This simulation modeling study using Phase-3 trial data evaluated tirzepatide versus semaglutide in individuals with obesity or overweight w…
Imagine standing in a doctor's office, facing a choice between two powerful weight-loss medicines.
Apr 22, 2026
Rheumatology
Sys. Review
Narrative review compares tirzepatide and semaglutide for obesity and type 2 diabetes outcomes.
New Obesity Drug Shows Stronger Weight Loss Than Popular Option
This narrative review evaluates tirzepatide versus semaglutide in individuals with obesity or type 2 diabetes mellitus. The authors synthesi…
This review shows that tirzepatide outperforms semaglutide for weight and blood sugar, but semaglutide currently has stronger proof for prot…
Frontiers
Apr 22, 2026
Psychiatry
Review of new-user target trial emulation comparing semaglutide and SGLT2i in U.S. Veterans with type 2 diabetes
Semaglutide Does Not Raise Suicide Risk, Study Finds
This active-comparator, new-user target trial emulation review synthesizes data from 102,361 U.S. Veterans with type 2 diabetes comparing se…
A large new study finds that semaglutide does not increase suicide risk compared to other diabetes drugs, easing fears for millions of patie…
medRxiv
Apr 21, 2026